Free
RxVigilance Mobile
⭐️0 / 5
Rating
🙌0
Ratings
📼5 scs
Content
📦~ in 0 month
Updates frequency
🗣❌ unsupported
Your locale
🧾$169.99
In-App Purchase
- Versions
- In-App Purchases History1
- Price History
- Description
- FAQ
All Versions of RxVigilance Mobile
2.0.110
June 26, 2024
July 2024
(monthly update)
Modifications to RxVigilance
=========================
Supplement in dialysis
Our team has reviewed the data on supplements in dialysis for hemodialysis (high-flux membrane) and peritoneal dialysis. You can consult the Supplement in dialysis section in the monographs, just below the Renal impairment section.
New monograph
=========================
Inebilizumab (Uplizma)
More2.0.109
May 31, 2024
June 2024
(monthly update)
Modifications to RxVigilance
=========================
Drugs used to treat osteoporosis
We've created a new comparative drug chart for drugs used to treat osteoporosis. Among other things, it contains information on the different classes of agents used, some treatment principles, as well as details on duration of treatment and drug holidays.
New monograph
=========================
Metreleptin (Myalepta)
Etrasimod (Velsipity)
More2.0.108
May 5, 2024
May 2024
(monthly update)
Modifications to RxVigilance
=========================
Comparative drug chart: Drugs used to treat obesity
We've created a new comparative drug chart for drugs used to treat obesity. Among other things, it contains information to help you compare the different treatment options (e.g.,recognized indications, usual doses, common side effects).
New monograph
=========================
Cannabidiol (Epidiolex)
Capivasertib (Truqap)
Rimegepant (Nurtec)
More2.0.107
March 29, 2024
April 2024
(monthly update)
New monograph
=========================
Avatrombopag (Doptelet)
Relugolix + estradiol + norethindrone (Myfembree)
Estradiol + Progesterone (Bijuva)
Odevixibat (Bylvay)
Ritlecitinib (Litfulo)
Foslevodopa + foscarbidopa (Vyalev)
More2.0.106
March 12, 2024
March 2024
(monthly update)
Modifications to RxVigilance
=========================
Comparative drug chart: Acne vulgaris
We've created a brand-new comparative drug chart for the drugs used to treat acne vulgaris. It contains information on the various topical and systemic products that may be used, as well as on the general principles of acne treatment.
New monograph
=========================
Vutrisiran (Amvuttra)
More2.0.105
February 7, 2024
February 2024
(monthly update)
Modifications to RxVigilance
=========================
Comparative drug chart: Dyslipidemia
In light of the 2023 update of the PEER simplified lipid guideline for the prevention and management of cardiovascular disease in primary care, we have updated our comparative drug chart for lipid-lowering agents, among others.
Notably, this update addresses the recommended follow-up when initiating a lipid-lowering treatment, treatment targets, and the management of certain adverse effects.
New monograph
=========================
Relugolix (Orgovyx)
Somapacitan (Sogroya)
More2.0.104
January 10, 2024
January 2024
(monthly update)
Modifications to RxVigilance
=========================
New developments in osteoporosis treatment
Following the publication of the new guideline for osteoporosis management and fracture prevention in the Canadian Medical Association Journal we have updated some of our content, including some bisphosphonate monographs.
This new guideline covers, among other things, drug holidays following three to six years of initial bisphosphonate treatment and the subsequent monitoring required to assess the need to resume treatment.
Enteric-coated ASA 80 mg
To avoid treatment interruption when enteric-coated (EC) ASA 80 mg is in short supply, there are two alternative options: chewable ASA 80 mg or ASA EC 81 mg.
There would be no significant difference in efficacy between the 80 and 81 mg doses. It is important to take into account the prescriber's or patient's perception of the importance of the enteric form. Although a recent study (JAMA Cardiol. 2023) shows that the risk of gastrointestinal adverse events appears similar between forms of ASA, further studies are considered necessary. Thus, it appears optimal to change ASA EC 80 mg to ASA EC 81 mg rather than the chewable form of ASA 80 mg.
New monographs
=========================
Mirikizumab (Omvoh)
Evinacumab (Evkeeza)
Cenobamate (Xcopri)
More2.0.103
December 7, 2023
November 2023
(monthly update)
Modifications to RxVigilance
=========================
Monographs
Our monograph for the new respiratory syncytial virus vaccine (Arexvy) is now available in RxVigilance. In addition, we have updated our COVID-19 vaccines monograph to reflect the new formulations available.
Comparative Drug Charts
We've updated the Breastfeeding section of the Antiretrovirals for the treatment of HIV infection comparative drug charts to incorporate the consensus recommendations from the Canadian Pediatric and Perinatal HIV/AIDS Research Group (CPARG).
New monographs
=========================
Respiratory syncytial virus (RSV) vaccine (Arexvy)
Vericiguat (Verquvo)
Cangrelor (Kengrexal)
Clascoterone (Winlevi)
Clevidipine (Cleviprex)
Nirsevimab (Beyfortus)
More2.0.102
November 8, 2023
November 2023
(monthly update)
Modifications to RxVigilance
=========================
Monographs
Our monograph for the new respiratory syncytial virus vaccine (Arexvy) is now available in RxVigilance. In addition, we have updated our COVID-19 vaccines monograph to reflect the new formulations available.
Comparative Drug Charts
We've updated the Breastfeeding section of the Antiretrovirals for the treatment of HIV infection comparative drug charts to incorporate the consensus recommendations from the Canadian Pediatric and Perinatal HIV/AIDS Research Group (CPARG).
New monographs
=========================
Respiratory syncytial virus (RSV) vaccine (Arexvy)
Vericiguat (Verquvo)
Cangrelor (Kengrexal)
Clascoterone (Winlevi)
Clevidipine (Cleviprex)
Nirsevimab (Beyfortus)
More2.0.101
October 4, 2023
October 2023
(monthly update)
Modifications to RxVigilance
=========================
Monographs
Following publication of the results of the TRAVERSE study in the New England Journal of Medicine, we have updated the Warnings sections of our monographs for testosterone-containing products. The alerts generated by our analysis engine have also been updated. The TRAVERSE study concluded that in men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events.
Comparative Drug Charts
We're currently redesigning our comparative drug charts. They will gradually be replaced by versions that are more streamlined and user-friendly. You can access these charts by going to the Comparative Drug Charts index at the bottom of the home screen or by using the Search field.
New monographs
=========================
Maralixibat (Livmarli)
Niraparib + abiraterone (Akeega)
MoreRxVigilance Mobile In-App Purchases History
$169.99
Subscription renewal
Extension of the subscription granting access to the monographs, the comparative charts and the interaction analysis for 12 months (including monthly updates).
MorePrice History of RxVigilance Mobile
Description of RxVigilance Mobile
RxVigilance - a reference tool for health care professionals that features information on drugs and health - can now be accessed from anywhere.
After installation, THE APPLICATION RESIDES ENTIRELY ON THE DEVICE and does not require an Internet connection for regular use. Internet access is required for updates.
Already used by thousands of physicians, pharmacists, nurses and other health care professionals across Canada, RxVigilance provides you with relevant and up to date information from several dozen leading reference sources. Drug monographs, pharmacological profile analysis, and information on natural products and travel destinations are among some of the many features you can now access through your device.
Our team of health care professionals is well aware of your day to day information needs. As a result, they are equipped to select what is most useful and relevant for you and your practice and to integrate that information to RxVigilance. In short, you will be able to access what you need quickly and effectively.
The RxVigilance Mobile App includes access to:
COMPARATIVE CHARTS
In the application users will find a series of charts comparing the characteristics of products from the same pharmacological class in order to help them make the best therapeutic decision based on onset of action or the number of administrations a day, for example.
MONOGRAPHS
Professional information on more than 1200 drugs. You can find information on adverse reactions, official and unofficial indications, adult dosages, pediatric dosages, geriatric dosages, adjustments for renal and hepatic impairment, precautions in pregnancy/breastfeeding, special precautions (grapefruit, stability, food, etc.), contraindications, interactions and kinetics. Monographs are regularly updated with information deemed relevant by our team of professionals.
TRAVEL
This feature allows to search for over 200 destinations. It provides access to brief and relevant overview of the destination (currency, languages, population, capital), required and/or recommended immunizations by country, recommendations based on diseases found in each country and contact details for service centres that may be of use while traveling.
NATURAL PRODUCTS
Information on more than 60 of the most commonly used natural products. It includes product indications (classified by evidence of effectiveness), product description and discussion on product safety and efficacy.
PROFILE ANALYSIS
Profile analysis allows to identify interactions and provides a description of the interactions as well as recommendations. Interactions are classified by importance of actions to be taken by the professional.
BULLETINS
Monthly communiqué for subscribers with details on the most recent updates and new developments and a list of monographs to which changes have been made. It is possible to refer to bulletins from prior months and send questions or comments via e-mail to the Rx Vigilance team.
PHONE DIRECTORY
A phone directory that consists of over 6000 useful contacts such as: hospitals, CLSCs, support groups and self-help groups, pharmacies, pharmaceutical companies, etc. It allows users to dial phone numbers directly from their iPhone and to acces links to internet sites when available.
Show less
RxVigilance Mobile: FAQ
Yes, RxVigilance Mobile is optimized for iPad devices.
Consultants Vigilance-Sante (1999) Inc is the developer of the app.
The app needs iOS 11.0 or later to function properly.
There is no information available about user ratings for RxVigilance Mobile.
The App Category Of The Rxvigilance Mobile App Is Medical.
The latest version of RxVigilance Mobile is 2.0.110.
The latest update for RxVigilance Mobile was released on July 5, 2024.
The app was initially released on February 5, 2023.
This app is for mature audiences only, and contains strong language, nudity, or sexual content.
Currently, the RxVigilance Mobile app supports the following languages: English, French.
Sorry, RxVigilance Mobile is not part of Apple Arcade.
Yes, RxVigilance Mobile is eligible for in-app purchases to enrich your usage.
No, RxVigilance Mobile does not offer compatibility with Apple Vision Pro.